SHR-7787

N/A

Report date: 2026/03/19 17:15:00

Base Information

Drug NameSHR-7787

Drug Alias NameSHR-7787SHR7787

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Delta-like protein 3Anti-CD3

TargetsDelta-like protein 3T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursSmall Cell Lung Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A